checkAd

     189  0 Kommentare Building a Better Future: Bristol Myers Squibb 2023 ESG Report - Seite 2

    Expanding the boundaries of science

    We are committed to scientific excellence and investment in our R&D capabilities to provide more medicines to more patients faster. We leverage our expertise to accelerate drug discovery and development, and we entrust our scientists to drive research and development to reduce the burden of diseases.

    We believe we have one of the most diversified portfolios and pipeline in the pharmaceutical industry. Thus, we are uniquely positioned to drive continued innovation and expand treatment options across therapeutic areas based on our differentiated research platforms that include cell therapy and targeted protein degradation.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    40,11€
    Basispreis
    0,39
    Ask
    × 10,68
    Hebel
    Short
    50,44€
    Basispreis
    0,59
    Ask
    × 6,88
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    These newly approved medicines and those in our near-term pipeline are the result of strong execution and collaboration across every part of our organization. Over the past three years, we have received more than 50 global regulatory approvals.

    As part of our commitment, we understand the importance of enrolling clinical trial populations that are more reflective of the real-world population and aligned with the epidemiology of the diseases we study. In doing so, we believe we can better address barriers to achieving health equity and deepen our clinicians' understanding of the safety and efficacy of transformative medicines for diverse populations.

    We know there is much work ahead to broaden these efforts to better understand what diversity in clinical trials means for other countries and across multiple patient characteristics.

    Building a better future. Learn more about the 2023 Bristol Myers Squibb ESG Report

    Lesen Sie auch

    Fostering a high-performing and inclusive global workforce

    Our values at BMS-Integrity, Innovation, Passion, Inclusion, Accountability and Urgency-are the foundation of our high-performing, patient-centric culture. Bringing these values to life enables our people to be at their very best so we can deliver for patients.

    Cultivating an inclusive and diverse workplace supports our ability to drive innovation. Our goal is to ensure our colleagues', patients' and communities' unique perspectives are heard and valued, and that everyone can contribute to our vision of transforming patients' lives through science. This begins with integrating inclusive practices across all facets of our organization, including our talent and engagement strategy, leadership development programs and online learning platforms.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Building a Better Future: Bristol Myers Squibb 2023 ESG Report - Seite 2 NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company:At Bristol Myers Squibb, our vision is to transform patients' lives through scienceOriginally published on Bristol Myers Squibb News & PerspectivesSince 1887, BMS has …

    Schreibe Deinen Kommentar

    Disclaimer